← Back to Search

Recombinant Factor VIII

efanesoctocog alfa (BIVV001) for Hemophilia A (XTEND-Kids Trial)

Phase 3
Waitlist Available
Research Sponsored by Bioverativ, a Sanofi company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up pre-dose, 0.25, 3, 24, 72, and 168 hours post-dose on day 1
Awards & highlights
Pivotal Trial
No Placebo-Only Group

Summary

This trial is testing BIVV001, a new treatment for children with hemophilia A. It aims to help their blood clot better by providing a necessary protein. The study will check if the treatment is safe and effective over several months. BIVV001 is a new type of treatment with a longer-lasting effect compared to traditional options.

Eligible Conditions
  • Hemophilia A
  • Hemophilia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~pre-dose, 0.25, 3, 24, 72, and 168 hours post-dose on day 1
This trial's timeline: 3 weeks for screening, Varies for treatment, and pre-dose, 0.25, 3, 24, 72, and 168 hours post-dose on day 1 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants With Neutralising Antibodies (Development of Inhibitors) Directed Against Factor VIII
Secondary study objectives
Annualized Bleeding Rate (ABR): For Treated Bleeds
Annualized Bleeding Rate by Location of Bleed (Joint, Muscle, Internal and Skin/Mucosa)
Annualized Bleeding Rate by Type of Bleed (Spontaneous, Traumatic and Unknown Type)
+44 more

Side effects data

From 2022 Phase 3 trial • 159 Patients • NCT04161495
20%
Headache
19%
Arthralgia
8%
Fall
6%
Back Pain
5%
Fatigue
2%
Haemophilic Arthropathy
1%
Cd4 Lymphocytes Decreased
1%
Mobility Decreased
1%
Ulnar Tunnel Syndrome
1%
Basal Cell Carcinoma
1%
Combined Tibia-Fibula Fracture
1%
Arthropathy
1%
Blood Glucose Increased
1%
Cubital Tunnel Syndrome
1%
Status Epilepticus
1%
Angina Pectoris
1%
Traumatic Haemorrhage
1%
Central Venous Catheter Removal
1%
Device Breakage
100%
80%
60%
40%
20%
0%
Study treatment Arm
Arm A: Prophylaxis
Arm B: On-demand
Arm B: Prophylaxis
BIVV001 (Efanesoctocog Alfa): All Participants

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: BIVV001: Participants aged <6 YearsExperimental Treatment1 Intervention
Participants aged less than (\<) 6 years received BIVV001 at a dose of 50 international units per kilogram (IU/kg) intravenous (IV) injection once-weekly (QW) prophylaxis for 52 weeks.
Group II: BIVV001: Participants aged 6 to <12 YearsExperimental Treatment1 Intervention
Participants aged 6 to \<12 years received BIVV001 at a dose of 50 IU/kg IV injection QW prophylaxis for 52 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
efanesoctocog alfa (BIVV001)
2021
Completed Phase 3
~240

Find a Location

Who is running the clinical trial?

Bioverativ, a Sanofi companyLead Sponsor
17 Previous Clinical Trials
962 Total Patients Enrolled
6 Trials studying Hemophilia A
593 Patients Enrolled for Hemophilia A
Clinical Sciences & OperationsStudy DirectorSanofi
871 Previous Clinical Trials
2,020,886 Total Patients Enrolled
9 Trials studying Hemophilia A
1,128 Patients Enrolled for Hemophilia A
~16 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top